Skip to Main Content

Paper Details

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Clin Cancer Res
20
2022
EGFR, Glioblastoma, H3F3Awt, H3F3Awt tumors, IDH, IDH-, IDH-wt, IDH1/2, IDH1/2 wildtype, IDH1/2wt, MGMT, MGMT promoter, Molecular abnormalities, Patients, TERT promoter, Temozolomide, anaplastic astrocytomas, central nervous system tumors, chromosome 10, chromosome 7, glioblastoma, isocitrate, isocitrate dehydrogenase-wildtype, patient, patients, temozolomide, tumors
Author NameAffiliation
Marc SansonSorbonne Universite, Inserm, CNRS, Paris Brain Institute - Institut du Cerveau (ICM), Hopitaux Universitaires La Pitie Salpetriere - Charles Foix
Michael A VogelbaumMoffitt Cancer Center
Warren P MasonPrincess Margaret Cancer Centre, University of Toronto
C Leland Rogers
Michael WellerClinical Neuroscience Center, University Hospital and University of Zurich
Kenneth AldapePrincess Margaret Cancer Centre, University of Toronto
Kenneth AldapePrincess Margaret Cancer Centre, University of Toronto
Johan M KrosErasmus MC Cancer Institute
Andreas von DeimlingRuprecht-Karls-University, and CCU Neuropathology German Cancer Institute and Consortium
Youri HoogstrateErasmus MC Cancer Institute
Pim J FrenchErasmus MC Cancer Institute
  • 1 - 11

Datasets

Release 1.2